Biologics Consulting Expands Management Team with the Addition of Kenneth P. Guito, MBA as Chief Operating OfficerHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Biologics Consulting Expands Management Team with the Addition of Kenneth P. Guito, MBA as Chief Operating OfficerGlobeNewswireJanuary 7, 2020ReblogShareTweetShareALEXANDRIA, Va., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Biologics Consulting, a full-service regulatory and product development consulting firm for biologics, pharmaceuticals and medical devices, announced today that Kenneth P. Guito, MBA was hired as its Chief Operating Officer (COO) following a 35-year career in the Biotech/Biopharmaceutical Industry. Mr. Guito’s broad career experience spans Operations, Corporate and Business Development, and Research and Development (R&D).Prior to joining Biologics Consulting, Mr. Guito worked with Sanofi Pasteur Inc. in many roles (1990-2015). Most recently, he served as General Manager at Sanofi-Topaz, Inc., a subsidiary company, where he was responsible for financial and operational activities for the company, including guiding the company’s first product through development, to FDA approval and commercialization.Prior to this role, he held senior level positions in Corporate and Business Development where he was responsible for the evaluation of in-licensing and M&A opportunities, and the execution of transactions. In 1990, he began his career at Sanofi Pasteur in R&D where he held senior leadership positions in Clinical Affairs, Product Development and Regulatory Affairs. During his tenure in R&D, he was a principal force in bringing nine small and large molecule products through development to commercial success.Earlier in his career, Mr. Guito was with Schering Corporation where he held the position of Sr. Director Clinical Affairs working as part of a team that licensed Alfa-2b interferon for chronic Hepatitis B and C; he began his career at Schering as a Sr. Scientist in Parasitology.“Ken’s scientific and business acumen will be invaluable in expanding our services and meeting the needs of our customers and stakeholders,” commented Norman W. Baylor, PhD, President and CEO of Biologics Consulting. “Ken and I worked many years across the table during my tenure at FDA and his at Sanofi, and I am very excited to now have the opportunity to work together with Ken on the same team. We both share a common goal of advancing public health by providing the best clinical, regulatory and manufacturing support to the regulated industry, NGOs and academic institutions.”About Biologics Consulting (www.biologicsconsulting.com) Biologics Consulting Group, Inc. is a full-service regulatory and product development consulting firm for biologics, pharmaceuticals and medical devices. Founded in 1993, Biologics Consulting has built a record of achievement, assisting clients worldwide with nonclinical, and clinical, product development and regulatory compliance challenges. Maddie Slezak 410-367-2700ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextMomenta's (MNTA) Q4 Loss Wider than Expected, Sales BeatZacksEditas (EDIT) Q4 Earnings & Sales Fall Shy of EstimatesZacksFacebook moves into a new Strip District office as its researchers imagine a future without office buildingsAmerican City Business JournalsWhite House’s top techie explains how AI initiative will help Seattle tech communityGeekWireModerna (MRNA) Beats Earnings Estimates in Q4, Revenues MissZacksBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo Finance